Page 5 - Aging Program News Today

The Food and Nutrition Research Institute of the Department of Science and Technology (DOST-FNRI) and University of the Philippines Manila-National Institute of Health, Institute on Aging (UPM-NIH-IOA) have teamed up to conduct a training for researchers who are involved in a research project on the

The Alzheimer Society of Huron County is back at it with its fall 2021 online education programs.

The Alzheimer Society of Huron County is back at it with its fall 2021 online education programs.

Bridge players finally reunify after COVID forced them online A group of Scottsdale bridge players has finally gotten back together in person after more than a year apart because of the pandemic. and last updated 2021-07-05 22:24:25-04 SCOTTSDALE, AZ — A group of Scottsdale bridge players has finally gotten back together in person after more than a year apart because of the pandemic. “Oh, its the best feeling in the world! You have your whole group of like all these people that you ha...

US lawmakers launch investigation into the controversial FDA approval of the first Alzheimers drug since 2003 and why it costs $56,000 The House Committee on Oversight and Reform and the House Committee on Energy and Commerce launch investigation into the controversial approval of Aduhelm The drug received approval despite mixed clinical trials results, though it did show it could potentially reduce cognitive decline by 22% Lawmakers are concerned about the drugs steep price tag, that will cost...

The Food and Drug Administration is on the verge of announcing one of its most contentious decisions in years: the fate of an Alzheimer’s drug that could be the first treatment approved after nearly two decades of failed efforts to find ways to curb the debilitating disease.

On Monday, the agency will rule on the drug, aducanumab, which aims to slow progression of memory and thinking problems early in the disease.

If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works.

The FDA is scheduled to announce a decision on aducanumab by Monday in one of its most closely watched rulings in years. The backstory of the drug, intended to delay cognitive decline in the early phase of Alzheimer’s disease, has been marked by soaring hopes and disheartening setbacks.

Alzheimers drug sparks emotional battle as FDA nears deadline on whether to approve Laurie McGinley, The Washington Post May 31, 2021 FacebookTwitterEmail 5 1of5A mental fog descended when Phil Gutis was diagnosed with Alzheimers. An experimental drug, he says, helped dissipate that fog, but now access to the medication could be imperiled.photo for The Washington Post by Rachel Wisniewski.Show MoreShow Less 2of5Tim Weaver pulls up a photo of his husband, Phil Gutis, being infused w...